Digoxin and fat tissue in people with heart failure and type 2 diabetes
Tests whether digoxin clears aging cells in fat tissue of adults.
Plain-language title generated from the registry record
Registry title: Digoxin and Senolysis in Heart Failure and Diabetes Mellitus
Key facts
- Where
- Leeds, United KingdomSee the site
- Phase
- Phase 2
Where in United Kingdom
- Leeds Teaching Hospitals NHS TrustLeeds, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Leeds
- Trial code
- NCT06240403
- Record updated
- 6 December 2024
- Original description
In pilot studies the investigators have shown that subcutaneous adipose tissue (SAT) from patients with reduced ejection fraction heart failure (HFrEF) and type 2 diabetes mellitus (T2DM) is dysfunctional. Endothelial cells from the adipose tissue from these patients are senescent and have deleterious effects on healthy human subcutaneous adipocytes, including increasing expression of IL-6 (gene and protein) and reducing glucose uptake. Digoxin, a well-established treatment for HFrEF, selectively clears these senescent endothelial cells and prevents adipocyte dysfunction. This study will examine the effect of digoxin on adipose tissue on the burden of senescent cells.Read full original descriptionShow less
Digoxin: a New Senolytic to Repair Dysfunctional Adipose Tissue in Patients With Heart Failure and Type II Diabetes Mellitus
In pilot studies the investigators have shown that subcutaneous adipose tissue (SAT) from patients with reduced ejection fraction heart failure (HFrEF) and type 2 diabetes mellitus (T2DM) is dysfunctional. Endothelial cells from the adipose tissue from these patients are senescent and have deleterious effects on healthy human subcutaneous adipocytes, including increasing expression of IL-6 (gene and protein) and reducing glucose uptake. Digoxin, a well-established treatment for HFrEF, selectively clears these senescent endothelial cells and prevents adipocyte dysfunction. This study will examine the effect of digoxin on adipose tissue on the burden of senescent cells.
Inclusion: Aged ≥18yrs,; HFrEF (LVEF<40%); T2DM (taking anti-diabetic medication, fasting plasma glucose ≥7.0 mmol/L and/or a serum HbA1c >48mmol/L; On optimal medical therapy,; Able/prepared to give informed written consent.
Exclusion: Current/previous (<6m) participation in other studies; Significant cognitive impairment,; eGFR<30ml/min/1.73m2; Important co-morbidity limiting ability to comply with study procedures,; Hyperkalemia (>5.5mmol/L).